Third‐generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease

Cresswell, Joanne; Asterling, S.; Chaudhary, Moazzam; Sheikh, N.; Greene, Damian

doi:10.1111/j.1464-410x.2006.06073.x

Cited by 56 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The routine placement of a thermosensor within the external sphincter decreases severe incontinence rates to ! 5% [32] , while prior transurethral resection of the prostate [23] and lack of a urethral warming catheter [28] increase the risk. The incidence of urethral sloughing (0-5%), persistent perineal pain (4-14%) and urinary retention (2-21%) also appears to be lower with third-generation systems, especially when a urethral warming catheter is used [34] .…”

Section: Discussionmentioning

confidence: 99%

Third-Generation Salvage Cryotherapy for Radiorecurrent Prostate Cancer: A Centre’s Experience

Philippou

Yap²,

Chinegwundoh³

2012

Urol Int

View full text Add to dashboard Cite

Introduction: The experience of a tertiary centre in the management of recurrent prostate cancer after radiotherapy by salvage cryotherapy is presented. Patients and Methods: Between February 2006 and August 2008, 19 patients underwent salvage cryotherapy for radiorecurrent prostate cancer. Post-radiotherapy recurrence was confirmed by prostatic biopsy. The ‘Phoenix definition’ was used to define biochemical failure after salvage cryotherapy. Results: The mean age at cryotherapy was 69.2 years and the mean time from radiotherapy to cryotherapy was 72.3 months. Patient characteristics prior to cryotherapy included a mean PSA level of 6.84 ng/ml and a median Gleason score of 7. The mean post-cryotherapy follow-up was 33.3 months. The 2-year biochemical disease-free survival rate was 58%. The median post-cryotherapy PSA nadir was 0.20 ng/ml (range 0.005–8.260). There were no procedure-related or cancer-related deaths. Complications included incontinence (10.5%), erectile dysfunction (89%) and fistula formation (5.3%). Conclusions: The relatively high rates of biochemical response support the use of cryotherapy as a salvage procedure for radiorecurrent prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Third-Generation Salvage Cryotherapy for Radiorecurrent Prostate Cancer: A Centre’s Experience

Philippou

Yap²,

Chinegwundoh³

2012

Urol Int

View full text Add to dashboard Cite

show abstract

“…In comparison, 10-year bDFS using the ASTRO criteria for combination EBRT and brachytherapy demonstrates slightly better results: 90%, 84%, and 48% for low-, medium-, and high-risk groups [15]. Table 1 provides data from the most recent publications (within the past 3 years) showing the respective long-and short-term bDFS rates for patients undergoing primary cryotherapy with third-generation systems only [3••,14•, [15][16][17].…”

Section: Primary Cryosurgerymentioning

confidence: 95%

Update on cryotherapy for localized prostate cancer

Ritch¹,

Katz

2009

Curr Urol Rep

View full text Add to dashboard Cite

Stage migration has led to an increased incidence of localized and low-risk prostate cancer. Intermediate-term data are emerging on the efficacy of cryotherapy, but direct comparison to other therapeutic modalities is difficult as the parameters for recurrence are not well defined. Studies using the American Society for Therapeutic Radiation and Oncology and the Phoenix (nadir plus 2) criteria for biochemical recurrence show that primary cryotherapy appears to be comparable for low-risk prostate cancer as other treatment modalities. In addition, health-related quality-of-life measures have improved with the most recent third-generation systems demonstrating low incontinence and urethrorectal fistula rates. Erectile dysfunction is high with whole gland ablation, but focal therapy may reduce these rates while still ablating unilateral cancerous tissue. Prostate cryotherapy for localized prostate cancer is an evolving but viable therapeutic option. Long-term data are still needed to establish a definitive role for cryosurgery in prostate cancer treatment.

show abstract

“…Salvage cryotherapy is an alternative minimally invasive technique that appears to be a valid option [28], however there is limited data available at present. Salvage brachytherapy has also been used as a potentially curative option, in a cohort of 49 patients, Grado et al [29] achieved a biochemical disease-free survival rate of 34% at 5 years, however further experience with this technique will need to be gained before it can be used more widely.…”

Section: Salvage Hifu Following Failure Of External Beam Radiotherapymentioning

confidence: 99%

The clinical applications of high intensity focused ultrasound in the prostate

Illing

Chapman²

2007

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

Third‐generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease

Cited by 56 publications

References 21 publications

Third-Generation Salvage Cryotherapy for Radiorecurrent Prostate Cancer: A Centre’s Experience

Third-Generation Salvage Cryotherapy for Radiorecurrent Prostate Cancer: A Centre’s Experience

Update on cryotherapy for localized prostate cancer

The clinical applications of high intensity focused ultrasound in the prostate

Contact Info

Product

Resources

About